Revance Therapeutics | Kostnadene For Salg

Cost Of Sales Endring Dato
AbbVie USD 4.28B 90M 2023-12
ALKERMES USD 61.51M 1.75M 2023-09
Eli Lilly USD 1.79B 72.1M 2023-12
Neurocrine Biosciences USD 11.2M 300K 2023-09
Pacira USD 47.69M 7.94M 2023-12
Supernus Pharmaceuticals USD 19.63M 26K 2023-12



Revance Therapeutics Kostnadene For Salg - Gjeldende verdier, historiske data, prognoser, statistikk, diagrammer og økonomiske kalender - Apr 2024.